Sign In
Buy TAK
$15.03
-0.150 (-0.99%)
At Close: Jun 03, 2026
Takeda Pharmaceutical: Diversify Your Book With This Excellent Japanese Pharma Play
01:53pm, Thursday, 28'th Oct 2021
Takeda is just off the back of its first half numbers where revenue rose double digits and annual guidance was confirmed.
Japan's Takeda half-year profit climbs, announces share buyback
02:46am, Thursday, 28'th Oct 2021
Japan's Takeda Pharmaceutical Co said on Thursday that its half-year profit rose 61% as the drugmaker tries to wring synergies out of its acquisition of Shire Plc. Operating profit was 346 billion yen
Takeda Expands Oncology Pipeline With Cell Therapy Startup Buyout
12:03pm, Wednesday, 27'th Oct 2021
Takeda Pharmaceutical Company Limited (NYSE: TAK) announced the exercise of its option to acquire GammaDelta Therapeutics Limited, a T cell startup. A little more than four years ago, Takeda step
2 of Sarah Ketterer's Stocks Sink Near 52-Week Lows
02:52pm, Tuesday, 26'th Oct 2021
While there are still a couple months left in 2021, some of Sarah Ketterer (Trades, Portfolio)'s holdings are potential buying opportunities currently.
Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs
06:54am, Tuesday, 19'th Oct 2021
Wave Life Sciences Ltd (NASDAQ: WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK) to discontinue discovery & research of preclinical programs for c
Calithera Buys Two Oncology Candidates From Takeda For $45M
06:51am, Tuesday, 19'th Oct 2021
Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK). The transaction terms include a to
Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M
06:21pm, Thursday, 14'th Oct 2021
Seattle-based cell therapy startup Immusoft will collaborate with pharma giant Takeda to develop treatments targeted to the central nervous system in a deal worth potentially more than $900 million.
A new deal with Takeda could mean up to $3.6 billion in milestone payments for Poseida Therapeutics
07:31am, Tuesday, 12'th Oct 2021
Shares of Poseida Therapeutics Inc. PSTX, +1.22% were up 9.6% in premarket trading on Tuesday after the company said it signed a research and licensing agreement with Takeda Pharmaceutical Co. Ltd. 45
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. Food and Drug Administration (FDA) Antimicrobial Dru
Why Takeda Pharmaceutical Stock Is Down More Than 10% Today
03:54pm, Wednesday, 06'th Oct 2021
The prescription drugmaker is halting a trial before a scheduled stopping point, suggesting it's too dangerous to expect an approval.
BofA Downgrades Takeda On Suspension Narcolepsy Drug Trials
11:35am, Wednesday, 06'th Oct 2021
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced the suspension of the Phase II trials of its narcolepsy drug candidate TAK-994 due to safety issues. Following the suspension of this promising pipeli
Takeda Discontinues Two Mid-Stage Narcolepsy Trials
05:54am, Wednesday, 06'th Oct 2021
Takeda Pharmaceutical Company Limited (NYSE: TAK) has suspended dosing and has decided to stop Phase 2 studies evaluating TAK-994, an investigational oral orexin agonist. According to Takeda, TAK 9
Takeda Provides Update on TAK-994 Clinical Program
07:33pm, Tuesday, 05'th Oct 2021
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a safety signal has emerged in Phase 2 studies of TAK-99
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
02:15pm, Friday, 01'st Oct 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new molecular entities, or NM
Takeda Says 'Human Error' Reason Behind Contaminated Moderna COVID-19 Vaccines
09:09am, Friday, 01'st Oct 2021
Takeda Pharmaceutical Co Ltd (NYSE: TAK) blamed "human error" as the cause of metal contaminants found in some batches of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine. The contamination led to the
